LivaNova PLC
LIVN55.000USD
-0.910-1.63%
Close 09/19, 16:00（ET）Quotes delayed by 15 min
3.00BMarket Cap
LossP/E TTM
More Details of LivaNova PLC Company
LivaNova PLC is a medical technology company. The Company designs, develops, manufactures, markets and sells products and therapies. Its segments include Cardiopulmonary, Neuromodulation and Advanced Circulatory Support (ACS). Cardiopulmonary segment is engaged in the design, development, manufacture, marketing and selling of cardiopulmonary products, including heart-lung machines (HLM), oxygenators, autotransfusion systems, perfusion tubing systems, cannula and other related accessories. It includes the Essenz Perfusion System, the Company’s next-generation HLM with an embedded patient monitor for tailored patient care strategies. Neuromodulation segment is engaged in the design, development, manufacture, marketing and selling of devices that deliver neuromodulation therapy for treating drug-resistant epilepsy (DRE) and difficult-to-treat depression (DTD). The ACS segment is engaged in the development, production, and sale of temporary life support products.
Company Info
Ticker SymbolLIVN
Company nameLivaNova PLC
IPO dateOct 19, 2015
CEOMr. Vladimir A. Makatsaria
Number of employees2900
Security typeOrdinary Share
Fiscal year-endOct 19
Address20 Eastbourne Terrace
CityLONDON
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited Kingdom
Postal codeW2 6LG
Phone442033250662
Websitehttps://www.livanova.com/
Ticker SymbolLIVN
IPO dateOct 19, 2015
CEOMr. Vladimir A. Makatsaria
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. William A. Kozy
Mr. William A. Kozy
Independent Chairman of the Board
Independent Chairman of the Board
32.57K
+15.05%
Mr. Alex Shvartsburg
Mr. Alex Shvartsburg
Chief Financial Officer
Chief Financial Officer
26.68K
--
Ms. Stephanie Bolton
Ms. Stephanie Bolton
President, Global Epilepsy
President, Global Epilepsy
12.75K
--
Dr. Sharon O'Kane, Ph.D.
Dr. Sharon O'Kane, Ph.D.
Independent Director
Independent Director
11.30K
+19.06%
Mr. Todd C. Schermerhorn
Mr. Todd C. Schermerhorn
Independent Director
Independent Director
9.06K
+49.63%
Mr. Francesco Bianchi
Mr. Francesco Bianchi
Independent Director
Independent Director
9.03K
-14.25%
Franco Poletti ,
Franco Poletti ,
President, Cardiopulmonary Business Unit
President, Cardiopulmonary Business Unit
8.52K
+4.49%
Ms. Brooke Story
Ms. Brooke Story
Independent Director
Independent Director
6.48K
+86.48%
Mr. Michael Damon Hutchinson
Mr. Michael Damon Hutchinson
Senior Vice President, Chief Legal Officer, Company Secretary
Senior Vice President, Chief Legal Officer, Company Secretary
5.67K
--
Ahmet Tezel
Ahmet Tezel
Senior Vice President, Chief Innovation Officer
Senior Vice President, Chief Innovation Officer
1.94K
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. William A. Kozy
Mr. William A. Kozy
Independent Chairman of the Board
Independent Chairman of the Board
32.57K
+15.05%
Mr. Alex Shvartsburg
Mr. Alex Shvartsburg
Chief Financial Officer
Chief Financial Officer
26.68K
--
Ms. Stephanie Bolton
Ms. Stephanie Bolton
President, Global Epilepsy
President, Global Epilepsy
12.75K
--
Dr. Sharon O'Kane, Ph.D.
Dr. Sharon O'Kane, Ph.D.
Independent Director
Independent Director
11.30K
+19.06%
Mr. Todd C. Schermerhorn
Mr. Todd C. Schermerhorn
Independent Director
Independent Director
9.06K
+49.63%
Mr. Francesco Bianchi
Mr. Francesco Bianchi
Independent Director
Independent Director
9.03K
-14.25%
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
No Data
By RegionUSD
Name
Revenue
Proportion
United States
169.16M
53.39%
Rest of World
87.99M
27.77%
Europe
59.70M
18.84%
By Business
By Region
No Data
Shareholding Stats
Updated: Tue, Aug 19
Updated: Tue, Aug 19
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
11.67%
PRIMECAP Management Company
8.50%
The Vanguard Group, Inc.
4.47%
Millennium Management LLC
4.44%
State Street Global Advisors (US)
3.81%
Other
67.10%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
11.67%
PRIMECAP Management Company
8.50%
The Vanguard Group, Inc.
4.47%
Millennium Management LLC
4.44%
State Street Global Advisors (US)
3.81%
Other
67.10%
Shareholder Types
Shareholders
Proportion
Investment Advisor
47.32%
Investment Advisor/Hedge Fund
34.23%
Hedge Fund
15.48%
Research Firm
3.07%
Pension Fund
2.18%
Bank and Trust
1.36%
Individual Investor
0.38%
Sovereign Wealth Fund
0.12%
Insurance Company
0.04%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
564
56.85M
104.11%
-6.95M
2025Q1
581
56.61M
103.82%
-8.04M
2024Q4
586
56.98M
104.84%
-8.56M
2024Q3
563
55.15M
101.56%
-9.48M
2024Q2
546
57.21M
105.64%
-8.52M
2024Q1
547
58.00M
107.51%
-6.90M
2023Q4
532
56.62M
105.11%
-7.28M
2023Q3
527
56.14M
104.20%
-8.51M
2023Q2
529
55.56M
103.33%
-9.55M
2023Q1
544
57.05M
106.52%
-4.67M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
6.53M
11.97%
-36.05K
-0.55%
Mar 31, 2025
PRIMECAP Management Company
4.61M
8.45%
-145.65K
-3.06%
Mar 31, 2025
The Vanguard Group, Inc.
2.65M
4.87%
+316.99K
+13.56%
Mar 31, 2025
Millennium Management LLC
2.07M
3.79%
-983.66K
-32.27%
Mar 31, 2025
State Street Global Advisors (US)
2.10M
3.85%
-950.00
-0.05%
Mar 31, 2025
AQR Capital Management, LLC
1.57M
2.88%
+829.12K
+111.71%
Mar 31, 2025
Dimensional Fund Advisors, L.P.
1.33M
2.44%
+20.96K
+1.60%
Mar 31, 2025
Geode Capital Management, L.L.C.
1.41M
2.59%
+73.94K
+5.53%
Mar 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
